Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients

Aziz Ogutlu1,2*, Ertugrul Guclu1,2, Oguz Karabay1,2, Aylin Calica Utku1, Nazan Tuna1 and Mehmet Yahyaoglu1

Abstract

Background: The consumption of carbapenems has increased worldwide, together with the increase in resistant gram negative bacilli. Subsequently, the prevalence of carbapenem-resistant Acinetobacter infections has increased rapidly and become a significant problem particularly in intensive care unit patients. The aim of the present study was to evaluate the changes in the prevalence of Acinetobacter infection by restricting the consumption of carbapenems in intensive care unit patients.

Methods: This study was conducted between May 1, 2011 and February 28, 2013. The amount of carbapenem consumption and the number of patients with multi-drug resistant Acinetobacter baumannii (MDRAB) isolates during the study period were retrospectively obtained from the records of the patients, who were hospitalized in the intensive care unit. The study period was divided into two periods named as: Carbapenem non-restricted period (CNRP) and carbapenem-restricted period (CRP). During CNRP, no restrictions were made on the use of carbapenems. During CRP, the use of carbapenems was not allowed if there was an alternative to carbapenems. Primary Endpoint: MDRAB infection after ICU admission. The definition of nosocomial infections related to Acinetobacter spp. was based on the criteria of the Center for Disease Control (CDC). The correlation between the amount of carbapenem consumption and the number of infections with MDRAB strains between the two periods were evaluated.

Results: During the study period, a total of 1822 patients’ (1053 patients in CNRP and 769 patients in CRP) records were evaluated retrospectively. A total of 10.82 defined daily dose (DDD/100 ICU days) of anti-pseudomonal carbapenem were used in CNRP, and this figure decreased to 6.95 DDD/100 ICU days in CRP. In the 8-month CNRP, 42 (3.98%) MDRAB-related nosocomial infections were detected, and 14 (1.82%) infections were detected in CRP (p = 0.012).

Conclusion: The prevalence of MDRAB strains isolated in the CNRP was 2.24-fold higher than the prevalence in the CRP. The prevalence of Acinetobacter infections can be reduced by taking strict isolation measures as well as by implementing good antibiotics usage policy.

Keywords: Carbapenem, Acinetobacter infection, Carbapenem consumption
Background

Nosocomial infections (NI) caused by multidrug-resistant gram negative bacilli have become a significant problem in recent years [1]. Micro-organisms isolated from NI vary depending on the changes in antibiotic usage policy. Acinetobacter spp. has an important place among the causes of NI [2].

Acinetobacter spp. rarely causes infections in a normal host due to their low virulence. However, this agent is the most important cause of infections in intensive care units (ICUs). Acinetobacter spp. cannot be totally eliminated from intensive care units despite numerous established infection control measures. NIs caused by Acinetobacter spp. are associated with morbidity and mortality, and lead to increases in the length of hospital stay, as well as in treatment costs [3]. Acinetobacter spp. remains viable for a long period of time in a hospital setting, and can be isolated from soil, water, and food. The bacteria can colonize in healthy individuals and in hospitalized patients [4]. One of the most important factors that play a role in the spread of Acinetobacter spp. is the ability of bacteria to easily develop resistance to antibiotics. In the 1990s, most Acinetobacter spp. was sensitive to quinolones and carbapenems. However, hospital outbreaks caused by multiple-drug-resistant Acinetobacter baumannii (MDRAB) are reported in many countries in the last 10 years [5]. The infection with resistant strains was associated with higher mortality rates, longer hospital stays, and higher treatment costs [6].

In order to develop a common language for the resistance problem, bacteria resistant to ≥3 antibiotics are called multi-drug resistant (MDR) bacteria, and those resistant to all antibiotics are called pan-resistant bacteria [7]. The most important risk factor for the infections caused by MDR strains is the previous use of broad spectrum antibiotics [8]. Carbapenems are the most effective antibiotics in the treatment of infections caused by resistant strains of Acinetobacter spp [9]. However, carbapenem-resistant Acinetobacter strains are increasing worldwide [2]. Previous studies have reported infection and/or colonization of carbapenem-resistant Acinetobacter baumannii as the independent predictor of previous use of carbapenems [10-12]. Moreover, undesired affects in bacterial ecology occurring as the result of antibiotic therapy are called collateral damage (CD). CD implies antibiotic-resistant bacteria, multi-drug resistant bacteria, and infections and colonization by Clostridium difficile [13,14]. Antimicrobial agents used for treatment purposes cause CD by affecting not only the infectious agent but also microflora. CD is more frequently pronounced with the use of broad spectrum antibiotics in the hospital setting. The selection rate of the resistant bacteria varies depending on the type of antibiotics administered. Antibiotics most commonly associated with CD include third generation cephalosporins, fluoroquinolones, and carbapenems [14,15].

Can restriction of the use of carbapenems, which are effective against Acinetobacter spp, result in a change in the prevalence of MDRAB? There are limited studies addressing this question. The present study was aimed to evaluate changes in the prevalence of MDRAB-related infections with the restriction of the use of carbapenems.

Methods

Study design and data collection

The present study was conducted in a 550-bed tertiary care hospital in Marmara region, Sakarya (Turkey), retrospectively. We evaluated the medical records of patients who were hospitalized in the intensive care units of Sakarya University Training and Research Hospital (STRH) from May 1, 2011 to February 28, 2013. There were 24 beds in ICUs in the study periods. The bed capacity was the same in the both periods. The average of 1360 ICU patients were followed over the last four years in ICUs (1141, 1305, 1356, and 1403 respectively). Both surgical and internal patients who need intensive care were followed in the general ICU. Neurological patients were followed in the neurology ICU. Patient characteristics were similar in the periods. Reanimaiton specialist was followed the patients in the general ICU. Neurologist was followed the patients in the neurology ICU. Infectious diseases specialists were consulted ICUs every day. The amount of carbapenem consumption and data relevant to isolated MDRAB strains were obtained from the medical charts.

Study periods

The study was conducted in two periods

Carbapenem non-restricted period (CNRP) and carbapenem-restricted period (CRP).

CNRP

Between May 1, 2011 and February 28, 2012. During this period, consulting physicians from the department of infectious diseases (CP) used carbapenem without any restriction in conditions they deemed appropriate. Carbapenem was not prescribed unless approved by the CP.

CRP

Between May 1, 2012 and February 28, 2013. The carbapenem usage was restricted during this period in the presence of an alternative therapy. The approval of the director of the department was sought for the use of carbapenem. Other CPs preferred alternative options other than carbapenem. During the carbapenem-restricted period, other options including piperacillin-tazobactam, cefoperazone-sulbactam, cefepime, Tigecycline, and colistin were allowed. No restriction was allowed if the strain was sensitive only to carbapenems.
Antibiotic consumption data

Normally, all of the specialists could prescribe all antibiotics except 15 ones that required approval from the infectious diseases specialist. MDRAB isolations were increased despite all of the infection control measures. Moreover, the Acinetobacter baumannii isolations were not susceptible to any drug except colistin. Some patients’ treatment were failed due to MDRAB infections. We searched the literatures, and then we decided to carbapenem restriction according to directives of infection control committee chairman. After the CNRP, we explained the carbapenem restriction and restriction requirement to the doctors. We did not do anything except carbapenem restriction.

Primary end-point

MDRAB infection occurring after admission to the intensive care unit.

MDRAB case definition

Patients from whom MDRAB was isolated and who were administered with carbapenem or other therapies for ≥72 hours during CNRP and CRP.

Inclusion criteria

Patients from whom MDR bacteria was isolated and who were diagnosed with systemic infection or pneumonia, and catheter, urinary tract, and wound site infection (the definition of MDR-related systemic infection, pneumonia, urinary tract, catheter, or wound site infection was made according to the criteria of the CDC [16]). Patients falling under the scope of item one and who received carbapenem or other therapy for at least 72 hours.

Exclusion criteria

Sensitive strains that did not meet MDR criteria.
Patients with missing data.
Patients who were considered to be colonization.
Patients in whom carbapenems are contraindicated.
Pregnant women.
Patients below the age of 18 years.

Multi-Drug Resistance (MDR)

Acquired non-susceptibility to at least one agent in three or more antimicrobial categories (ampicillin/sulbactam, aztreonam, ceftazidime, ciprofloxacin, gentamicin, imipenem, piperacillin-tazobactam and trimethoprim/sulfamethoxazole) or resistance to >1 agent in ≥3 different groups of antibacterial including carbapenems [17].

Statistical analysis

Epi-info (CDC, Atlanta, USA) 6.0 software was used in the statistical analysis. P values <0.05 were considered significant.

The study was designed as a retrospective study. Therefore, approval was not obtained from the ethics committee.
Results
During the study period, a retrospective review of the records of 1822 patients (1053 patients (57.85%) in CNRP and 769 (42.2%) patients in CRP) was evaluated. Carbapenem consumption was described as DDD/100 ICU days by months (Figure 1). A total of 10.82 defined daily dose (DDD/100 ICU days) of anti-pseudomonal carbapenem were used in CNRP, and this figure decreased to 6.95 DDD/100 ICU days in CRP. There was also an increase in the number of ertapenem (0.32 DDD/100 ICU days/0.76 DDD/100 ICU days) and amikacin (0.49 DDD/100ICU days/0.65 DDD/100 ICU days). During the study, MDRAB were isolated in total of 56 (3.1%) patients. MDRAB were isolated from 42 patients (3.98%) in CNRP, and from 14 patients (1.82%) in CRP (p = 0.012). The prevalence of MDRAB strains isolated in the CNRP was 2.24-fold higher than the prevalence in the CRP (Table 1). While Pseudomonas aeruginosa isolations were increased in the CRP, Staphylococcus aureus isolations were decreased (Figure 2).

Nosocomial infection density was 8.75 for 1000 patient days in CRP while nosocomial infection density was 19.70 in CNRP.

Discussion
This study showed that the restriction of carbapenems in the intensive care units would cause a 2.24-fold reduction in the prevalence of MDRAB infections (p = 0.012). Accordingly, strictly restricting carbapenems in intensive care units may play a role in preventing outbreaks of MDRAB.

Anti-pseudomonal carbapenems are the choice of first line drugs in the treatment of infections by Acinetobacter spp. MDRAB strains are rapidly increasing due to the inappropriate use of carbapenems and other broad spectrum antibiotics. A 77% resistant rate has been reported in Acinetobacter strains isolated from ICU patients in 2012, in Turkey [18]. Therefore, carbapenems may not be the first choice in the ICU in Turkey. Uncontrolled consumption is one of the most important factors that rendered carbapenems useless in the treatment of Acinetobacter infections [19]. While depleting antibiotic arsenal for use in infections caused by resistant bacteria, further strategies need to be implemented to maintain the effectiveness of current antibiotics for longer duration in clinical use.

The prevalence of resistant Acinetobacter strains are higher in countries such as Greece, Turkey, and Italy, where carbapenems are intensely used, and the prevalence is lower in countries such as Holland, and Scandinavian countries [20,21].

Anti-microbial agents cause CD by not only affecting the infectious agent, but also affecting the micro flora of the hospital. The selection rate of the resistant bacteria varies depending on the type of antibiotics employed. Compared to other broad spectrum antibiotics, carbapenems also increase the colonization of MDR-Acinetobacter, MDR-Pseudomonas aeruginosa, carbapenemase-positive Klebsiella and C.difficile through CD [15,22]. In the present study, the isolation of a higher number of MDRAB

Table 1 The effect of carbapenem restriction on multi-drug resistant Acinetobacter baumannii isolation

| Carbapenem restriction period | Number of patient n (%) | Number of patients with Acinetobacter isolated n (%) | Odds ratio (OR) (95% CI) | P value |
|-----------------------------|-------------------------|---------------------------------------------------|------------------------|--------|
| No                          | 1053 (57,7)             | 42 (3,9)                                          | 2.24 (1.18-4.33)       | 0.012  |
| Yes                         | 769 (42,2)              | 14 (1,8)                                          |                        |        |
| Total                       | 1822                    | 56 (3,0)                                          |                        |        |
in the CNRP is thought to be associated with CD. The antibiotics most commonly associated with CD include third generation cephalosporins, fluoroquinolones, and carbapenem [14,15]. In the present study, we think that lower prevalence of Acinetobacter infections in the CRP was due to the change in normal micro flora in the hospital.

In the literature, the studies suggest previous carbapenem consumption as a risk factor for MDR-Acinetobacter infections [23-25]. Our study results showed that all the microorganism isolations were decreased except Staphylococcus aureus in the CRP. A positive correlation was observed with anti-pseudomonal carbapenem (imipenem and meropenem) consumption and the development of resistance in Acinetobacter and Pseudomonas in a study which made in India [3]. MDRAB infections were shown to increase 16 times by using antipseudomonal carbapenem in a study conducted in Taiwan (19). Moreover, this increased resistance was not shown in any antimicrobial group except carbapenem. In this study, the importance of restriction in the use of antipseudomonal carbapenem was emphasized for the decreasing and controlling of the MDR-Acinetobacter infection [19]. This situation may be due to selection of MDR-Acinetobacter which could be become resistant easily with broad-spectrum antibiotics such as carbapenem. We also think the requirements of rational antibiotic use policies for reduce the spread of MDR-Acinetobacter spp.

One study showed a significant reduction in the isolation of MDR-Acinetobacter strains in association with carbapenem restriction [26]. However, antibiotic stewardship programs alone are not sufficient to prevent Acinetobacter infections. Hand hygiene and other isolation measures are as important as antibiotic management.

Before any conclusion we should declare limitations of our study. This study was done only with a limited number of cases in a single center. If the number of cases were much more, study could has been more power. If we could be watched the genotypic changes in the bacterial resistance between the study periods, our results could have been more effective.

In conclusion, the strict restriction of carbapenem use is an important strategy to reduce the prevalence of MDR-Acinetobacter strains. However, all precautions (i.e. barrier measures, hand washing, sterilization, and disinfection) should be taken in intensive care units with the goal of achieving a "0%" infection rate.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
AO and OK designed the study, prepared the literature, analyzed and interpreted the data, and wrote the manuscript; EG, ACU, NT and MY collected the data about carbapenem consumption and MDRAB isolates. All authors read and approved the final manuscript.

Acknowledgments
We thank the staff of the Department of Microbiology for their contributions in performing microbiological tests.

Author details
1Sakarya University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Sakarya, Turkey. 2Sakarya University, Health Science Institute, Sakarya, Turkey.

Received: 15 November 2013 Accepted: 1 January 2014 Published: 9 January 2014

References
1. Berezin BE, Towner KJ: Acinetobacter spp as nosocomial pathogens. Microbiological, clinical and epidemiological features. Clin Microbiol Rev 1996, 9:148–165.
2. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA: Global challenge of multidrug resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51:3471–3484.
3. Jaggi N, Sissodja P, Sharma L: Control of multidrug resistant bacteria in a tertiary care hospital in India. Antimicrob Resist Infect Control 2012, 61:123.
4. Paterson DL: Serious infections in the intensive care unit: Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 2005; 43:2541–524.
5. Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21:538–582.
6. Sunenshine RH, Wright MD, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Amla C, Jernigan DB, et al: Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13:167–169.
7. Arman D: Challenges with Gram Negative Bacteria in Intensive Care Unit. Ankeny Derm 2009, 23:148–156.
8. Young LS, Sabel AL, Price CS: Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter-baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol 2007, 28:1247–1254.
9. Ural S, Garcia-Rodriguez JA: Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002–2004. Diagn Microbiol Infect Dis 2005, 53:265–271.
10. Tzia HT, Wang J, Chen CJ, Chang SC: Association between antibiotic usage and subsequent colonization or infection of extensive drug-resistant Acinetobacter baumannii: a matched case-control study in intensive care units. Diagn Microbiol Infect Dis 2008, 62:298–305.
11. Paterson DL: The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006, 43:543–548.
12. del Mar TM, Cartelle M, Pertega A, Becoira A, Linares P, Carle D, Molina F, Villanueva R, Crespo: JM, Bou G: Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacterbaumannii, patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005, 11:540–546.
13. Paterson DL: “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004, 38:341–345.
14. Rice LB: Collateral damage. Ann Intern Med 2003, 139:523–524.
15. Goldstein EJC: Beyond the target pathogen: ecological effects of the hospital formulary. Curr Opin Infect Dis 2011, 24:21–31.
16. Horan TC, Andrus M, Dudek MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:S309–332.
17. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Herbut S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for new clinical definitions for acquired resistance. Clin Microbiol Infect 2012, 18:228–281.
18. National nosocomial infections surveillance network (UHESA) report. Summarized data; 2012. http://uhes.saglik.gov.tr/public/indir/UHESA%20ANAL%C4%B0Z-2012.pdf.
19. Hsieh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, Luh KT: Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002, 8:827–832.
20. Gur D, Korten V, Ural S, Deshpande LM, Castanheira M: Increasing carbapenem resistance due to the clonal dissemination of oxacillinase.
21. Adriaenssens N, Coenen S, Versporten A, Muller A, Minalu G, Faes C, Vankerckhoven V, Aerts M, Hens N, Molenberghs GN: European surveillance of antimicrobial consumption (ESAC): outpatient antibiotic use in Europe (1997–2009). J Antimicrob Chemother 2011, 66:vii3–vii12. http://ecdc.europa.eu/en/activities/surveillance/ESAC-Net/about_ESAC-Net/Pages/about_network.aspx.

22. Şener B: Collateral damage and antibiotic resistance. ANKEM Derg 2011, 26:288–292.

23. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T, Cayuela A, Marquez-Vácaro JA, Garcia-Curiel A, Jiménez-Jiménez FJ: Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005, 31:649–655.

24. Lee SO, Kim NJ, Choi SH, Hyong Kim T, Chung JW, Woo JH, Ryu J, Kim YS: Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case control study. Antimicrob Agents Chemother 2004, 48:224–248.

25. Corbella X, Montaner A, Pujol M, Domínguez MA, Ayats J, Argerich MJ, Gargiulosa F, Araù J, Gudiol F: Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000, 38:4086–4095.

26. Xue XS, Wang B, Deng LJ, Kang Y: Carbapenem restriction reduce the incidence of multidrug-resistant Acinetobacter baumannii in ventilator associated pneumonia. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2009, 21:234–236. (Abstract) [Article in Chinese].

(0X23 and OXA-58) producing Acinetobacter baumannii: report from the Turkish SENTRY program sites. J Med Microbiol 2008, 57:1529–1532.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit